Darren Shafren

Professional Summary: Professor Darren Shafren

Professor Darren Shafren is a distinguished academic and researcher affiliated with the University of Newcastle, Australia. With a focus on virology and oncology, he has made significant contributions to the field of oncolytic virotherapy, particularly in the development of novel cancer treatments using viruses. His work bridges fundamental science and clinical application, earning him recognition as a leader in his field.

Academic Background and Degrees

Professor Shafren holds advanced degrees in science and virology, though specific details of his educational background are based on publicly available records of his expertise and career progression at the University of Newcastle. His academic training has equipped him with a deep understanding of molecular biology and viral mechanisms, which underpin his research career.

Research Specializations and Academic Interests

Professor Shafren’s research primarily focuses on:

• Oncolytic virotherapy, particularly the use of coxsackievirus as a therapeutic agent for cancer treatment.
• Molecular mechanisms of viral infection and host interaction.
• Translational research to develop innovative cancer therapies.

His work aims to harness viruses to selectively target and destroy cancer cells, offering potential new avenues for treatment in oncology.

Career History and Appointments

Professor Shafren has held several key positions during his academic career, including:

• Professor at the University of Newcastle, School of Biomedical Sciences and Pharmacy.
• Researcher and collaborator with the Hunter Medical Research Institute (HMRI), focusing on cancer research.

His long-term association with the University of Newcastle underscores his commitment to advancing medical research in Australia.

Major Awards, Fellowships, and Honors

While specific awards and honors are not widely documented in public sources, Professor Shafren’s leadership in oncolytic virotherapy research and his contributions to cancer treatment development are widely acknowledged within the scientific community. His work has been supported by various research grants and collaborative funding initiatives.

Key Publications

Professor Shafren has authored numerous peer-reviewed articles in high-impact journals. Some of his notable publications include:

• Shafren, D. R., et al. (2004). 'Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule-1 for cell entry.' Journal of Virology.
• Shafren, D. R., et al. (2005). 'Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus A21.' Clinical Cancer Research.
• Shafren, D. R., et al. (2014). 'Oncolytic immunotherapy for treatment of cancer using coxsackievirus A21.' Immunotherapy.

These publications highlight his pioneering work in using viruses as therapeutic agents for cancer treatment.

Influence and Impact on Academic Field

Professor Shafren’s research has had a transformative impact on the field of oncolytic virotherapy. His studies on coxsackievirus A21 as a potential cancer treatment have contributed to the development of clinical trials and the founding of Viralytics, a biotechnology company focused on oncolytic immunotherapy. His work has paved the way for innovative approaches to cancer treatment, influencing both academic research and industry applications. In 2018, Viralytics was acquired by Merck & Co., underscoring the global significance of his contributions.

Public Lectures, Committees, and Editorial Contributions

While specific details of public lectures or editorial roles are not extensively documented in public sources, Professor Shafren is known to have presented his research at international conferences and collaborated with global research networks. His involvement in the scientific community likely includes contributions to peer review and advisory roles in cancer and virology research initiatives.